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Abstract  14 
Polylactide (PLA) polymers containing five distinct lengths of fluorinated (from C3F7 to C13F27) 15 
and non-fluorinated (C6H13) end-groups were successfully synthesized by ring-opening 16 
polymerization of D,L-lactide. Fluorination was expected to increase the encapsulation 17 
efficiency of perfluorohexane (PFH). 150 nm nanocapsules were obtained and 19F nuclear 18 
magnetic resonance revealed that nanocapsules formulated with fluorinated polymers 19 
increased by 2-fold the encapsulation efficiency of PFH compared with non-fluorinated 20 
derivatives, without any effect of fluorine chain length. Fluorination of the polymers did not 21 
induce any specific in vitro cytotoxicity of nanocapsules towards HUVEC and J774.A1 cell 22 
lines. The echogenicity of fluorinated-shelled nanocapsules was increased by 3-fold to 40-23 
fold compared to non-fluorinated nanocapsules or nanoparticles devoid of a perfluorohexane 24 
core for both fundamental and harmonic ultrasound imaging modalities. In particular, an 25 
enhanced echogenicity and harmonic response was observed as the fluorinated chain-length 26 
increased, probably due to an increase of density and promotion of bubble nucleation. When 27 
submitted to focused ultrasound, both intact and exploded nanocapsules could be observed, 28 
also with end-group dependency, indicating that PFH was partly vaporized. These results 29 
pave the way to the design of theranostic perfluorohexane nanocapsules co-encapsulating a 30 
drug for precision delivery using focused ultrasound.  31 
Keywords: Nanocapsules, perfluorohexane, fluorinated polymers, ultrasound imaging, 32 
focused ultrasound, fluorous interactions; cell viability.33 
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1. Introduction 34 
Ultrasound contrast agents (UCAs) are efficient intravascular echo-enhancers 35 
currently indispensable to safe and accurate diagnosis of many diseases, including kidney 36 
cists [1], acute myocardial ischemia [2]  and solid tumors [3]. All the commercially available 37 
UCAs, such as Definity® and Sonovue®, are microbubbles constituted by a perfluorinated 38 
gaseous-core stabilized by a monolayer of phospholipids [4]. Unfortunately, the imaging and 39 
therapeutic applications of such materials are severely limited by (1) the fast-diffusing gas 40 
component, responsible for a relatively short distribution half-life in the bloodstream (~60s 41 
after bolus injection) and an elimination half-life of about 6 minutes [5, 6], and (2) their 42 
inherent micrometer size range that prevents extravasation into solid tumors.  43 
To overcome these limitations, research has focused on nanosystems that can be 44 
more stable and are able to diffuse beyond the vascular compartment. Since gas 45 
nanobubbles are difficult to stabilize [7], the strategy has consisted in encapsulating liquid 46 
perfluorocarbons (PFCs) into nanoemulsions using surfactants or in polymer nanocapsules 47 
[8]. Although interesting, this approach leads to a significant reduction of the echogenicity. 48 
Indeed, as the scattering cross section of a particle is defined according to equation 1, a 49 
reduction of size and the replacement of the gas core by a liquid one, induce a decrease of 50 
the scattering cross section and subsequently of echogenicity.  51 
     
  
 
      
     
 
 
 
 
 
 
       
 
        
 , Eq. 1 52 
where k is the wavenumber, R is the radius of the particle, κd and κ the 53 
compressibilities of respectively the particle and the medium, ρd and ρ the densities of 54 
respectively the particle and the medium [9].  55 
To provide strong and long-lasting ultrasonic echoes, liquid PFCs of low boiling point, 56 
such as perfluorohexane (PFH) or perfluoropentane, have been selected for their ability to 57 
experience a liquid-to-gas transition once exposed to high acoustic pressures [10]. During 58 
this phenomenon – known as acoustic drop vaporization (ADV) – the PFC vapor phase 59 
undergoes oscillations around an equilibrium radius, which enhances the ultrasound 60 
scattering intensity of nanometric systems by several orders of magnitude [11-16]. An 61 
advantage of nanocapsules over microbubbles is their ability to co-encapsulate a drug for 62 
further therapeutic use [17]. As previously reported, PFC-containing nanocapsules can 63 
preserve their integrity and initial diameter after intravenous administration and passively 64 
accumulate in tumor tissues through the enhanced permeability and retention effect (EPR) 65 
[17-20] provided this effect occurs in patients [21]. After reaching tumor tissue, the release of 66 
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a co-encapsulated drug might be triggered by focused ultrasound (FUS), causing local PFC 67 
cavitation/vaporization and may be followed by capsule shell rupture with subsequent drug 68 
release [22]. This strategy is currently investigated to deliver higher drug concentrations in 69 
the tumor vicinity and increase the chemotherapy efficacy while avoiding unwanted toxicity to 70 
healthy cells [23]. As FUS is clinically employed to ablate and eradicate tumor cells, 71 
particularly in prostate [24] and hepatocellular carcinomas [25], it represents an ideal trigger 72 
for drug delivery because it is a non-invasive technique, safe to adjacent tissues and 73 
provides a precise spatiotemporal control over the thermal and mechanical energy 74 
dissipation [26].  75 
Before pushing forward these theranostic applications, the efficient encapsulation of 76 
low boiling point PFCs is required. Contrary to high boiling point PFCs such as 77 
perfluorooctylbromide, the entrapment of low boiling point PFCs such as PFH into polymeric 78 
nanosystems is a challenging process due to their fluorophilic character and high vapor 79 
pressure [27, 28]. Perfluorinated compounds are usually immiscible with hydrophilic or 80 
hydrophobic solvents due to favored interactions between fluorinated domains [29]. 81 
Accordingly, perfluorinated liquids tend to phase-separate, resulting in low encapsulation 82 
efficiencies – from 3 to 9% in nano-sized formulations [30, 31] – which represents a limitation 83 
for ultrasound imaging and ultrasound-triggered drug delivery. To promote better PFH 84 
encapsulation into nanocapsules, we have synthesized polylactide (PLA) polymers 85 
terminated by linear fluorinated end-groups of distinct lengths. The presence of the 86 
fluorinated moiety is expected to increase PFH encapsulation efficiency by playing on 87 
fluorous-fluorous interactions as it was observed for another PFC: perfluorooctyl bromide 88 
[32]. Polymer synthesis, nanocapsule formulation and characterization are reported. Finally, 89 
the nanocapsule echogenicity and ability to be destroyed by focused ultrasound is evaluated.    90 
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2. Materials and Methods 91 
2.1 Materials 92 
D,L-lactide was purchased from Polysciences (Germany) and perfluorohexane 93 
(purity>98%) was acquired from Alfa Aesar (Germany). 1-hexanol from Acros Organics 94 
(Belgium), 2,2,3,3,4,4-heptafluoro-1-butanol, 1H,1H perfluoro-1-heptanol, 1H,1H perfluoro-95 
1-nonanol, 1H,1H perfluoro-1-dodecanol and 1H,1H perfluoro-1-tetradecanol were acquired 96 
from Fluorochem (United Kingdom). Acetone, tetrahydrofuran (THF) and dichloromethane 97 
were purchased from Carlo Erba Reactifs (France), chloroform and diethyl ether from VWR 98 
(France). Stannous octoate, dry toluene, D2O, sodium cholate, trifluoroacetic acid (TFA) 99 
and polyvinyl alcohol (PVA, 30-70kDa, 87-90% hydrolyzed) were provided by Sigma-Aldrich 100 
(France). Deuterated solvents (CDCl3 and acetone-d) were purchased from Eurisotop 101 
(France), Cell culture reagents such as DMEM (Dulbecco’s modified Eagle’s medium), 102 
RPMI 1640 (Roswell Park Memorial Institute medium), FBS (Fetal Bovine Serum), trypsin-103 
EDTA solution and PBS (Ca2+ and Mg2+ free phosphate buffer) were purchased from Sigma 104 
Aldrich (France). The ultrapure water was produced by a Millipore Synergy 185 apparatus 105 
coupled with a RiOs5TM (Millipore, France) with a resistivity of 18.2 MΩ.cm. The NMR 106 
sample tubes and coaxial inserts were obtained from CortecNet (France). 107 
2.2 Polymer Synthesis 108 
All fluorinated (PLA-C3F7, PLA-C6F13, PLA-C8F17, PLA-C11F23 and PLA-C13F27) and 109 
non-fluorinated (PLA-C6H13) derivatives of polylactide polymers were synthesized by ring 110 
opening polymerization (ROP) with the presence of stannous octoate as catalyst [33] [34]. 111 
All glassware and stir bars were flame-dried and cooled under argon flow. Briefly, in a 10 112 
mL schlenck tube equipped with a magnetic stir-bar, the D,L-lactide (10.4 mmol, 1.5g) and 113 
corresponding initiator (0.075 mmol) – 1-hexanol for PLA-C6H13, 2,2,3,3,4,4-heptafluoro-1-114 
butanol for PLA-C3F7, 1H,1H perfluoro-1-heptanol for PLA-C6F13, 1H,1H perfluoro-1-115 
nonanol for PLA-C8F17, 1H,1H perfluoro-1-dodecanol for PLA-C11F23 or 1H,1Hp-1-116 
tetradecanol for PLA-C13F27 – were added to the flask under argon flow. The tube was 117 
sealed with a rubber cap and a stannous octoate solution (0.05 mmol, 20 mg) dissolved in 2 118 
mL of dried toluene was added through the septum. The tube was purged with argon for 119 
0.5h and the polymerization reaction was conducted with continuous stirring at 130°C for 55 120 
minutes in an oil bath under argon flow. The reaction was quenched by immersing the flask 121 
in a cold water bath. Afterwards, the solvent was evaporated under reduced pressure for 1h 122 
and the material was dissolved in 5 mL of chloroform. The product was purified by 123 
precipitation as previously described [20]: all polymers were precipitated into cold diethyl 124 
ether (80 mL), next, PLA-C6H13 was dissolved into THF (5mL), whereas the fluorinated 125 
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polymers were dissolved in acetone (20 mL) and precipitated again in ultrapure water (150 126 
mL). The samples were freeze-dried for 24h and a white powder was obtained. Lactide 127 
conversion ≥95% (1H-NMR). 1H-NMR [400 MHz, CDCl3, 25°C] PLA-C6H13: δH 5.10-5.28 128 
(PLA-CHCH3COO-), 1.52-1.61 (-CCH3), 0.88-0.92 (-CH2CH3). PLA-C3F7, PLA-C6F13, PLA-129 
C8F17, PLA-C11F23 and PLA-C13F27: δH 5.10-5.28 (PLA-CHCH3COO-), 4.50-4.70 (-130 
OCH2CF2-), 1.52-1.61 (-CCH3). 
19F-NMR [200 MHz, CDCl3, 25°C] PLA-C3F7: δF -78.9 to -131 
79.05 (-CF3), -118.5 to -119 (-CH2CF2-) and -125.7 to 125.8 (–CF2CF2CF3); PLA-C6F13, 132 
PLA-C8F17, PLA-C11F23 and PLA-C13F27: 
19F-NMR [400 MHz, CDCl3, 25°C]: δF -78.8 to -133 
79.05 (-CF3), -117.6 to -117.9 (-CH2CF2), -120.0 to -120.6 (-CF2CF2CF3), -120.7 to -121.2 (-134 
CH2CF2CF2), -121.2 to -121.6 (-CH2CF2CF2CF2) and -124.0 to -124.5 (-CF2CF3).  135 
2.3 Characterization 136 
All polymers were characterized by size exclusion chromatography (SEC) in 137 
chloroform at 30°C with a flow rate of 1 mL.min-1 by two columns (PL-gel 5µm MIXED-D 138 
300 x 7.5 mm) calibrated against a curve based on poly(methyl methracrylate) standards 139 
(PMMA, Polymer Laboratories, Varian Inc.). The system was coupled to a refractive index 140 
detector (Spectrasystem RI-150, Thermo Electro Corp.). 1H and 19F-NMR spectra were 141 
obtained on a Bruker Advance 400 MHz in CDCl3 at room temperature.  142 
2.4 Differential Scanning Calorimetry (DSC) 143 
All polymers were sealed in aluminum pans (50 μL) and placed in a DSC apparatus 144 
(DSC Q1000, TA Instruments). All analyses were conducted under nitrogen flow 145 
(20 mL.min-1) in a temperature range between 20 and 70°C at a heat and cooling rate of 146 
20°C.min-1. The glass transition temperature was determined during the second heating 147 
run. 148 
2.5 Nanocapsules Formulation 149 
Nanocapsules (NCs) were prepared by the emulsion-evaporation technique, as 150 
previously described with modifications[19]. Briefly, 50 mg of polymer was dissolved in 2 151 
mL of chloroform in a 50 mL glass flask that was sealed with a rubber cap. Next, 30 µL of 152 
PFH was introduced through the septum with constant stirring, and the media was 153 
emulsified with 10 mL of sodium cholate 1.5% (w/w) at 4°C in a vortex for 1 min. The 154 
mixture was then submitted to probe sonication (Branson digital sonifier, France) at 30% of 155 
maximal power for 1 min over ice. The solvent was evaporated by magnetic stirring at 300 156 
RPM during 4h in a thermostated bath at 20°C. The samples were then filtered on 0.45 µm 157 
PVDF filters (Whatman) and incubated with PVA 1% w/w for 5 days at 4°C. Finally, they 158 
were centrifuged at 27.240 g (Optima LE-80K Ultracentrifuge Beckman Coulter, France) 159 
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during 1h at 4°C and the pellet was resuspended in 5 mL of ultrapure water to yield a final 160 
polymer concentration of 25 mg.mL-1.  161 
 162 
2.6 Size and ζ-potential  163 
The hydrodynamic diameter, polydispersity index (PdI) and zeta potential of 164 
nanocapsules were measured using a Zetasizer Nano ZS (Malvern, France) at 20°C. All 165 
suspensions were diluted 1:10 in ultrapure water for size measurements and 1 mM NaCl for 166 
zeta potential measurements.  167 
2.7 Electron Microscopy 168 
Scanning electron microscopy was performed using a Merlin 6040 (Carl Zeiss, 169 
Germany) operating at 3 kV. The nanocapsules were deposited on carbon conductive 170 
double-sided tape (Euro-medex, France) and dried at room temperature. Afterwards, they 171 
were coated with a palladium–platinium layer of about 3 nm using a Cressington sputter-172 
coater 208HR with a rotary-planetary-tilt stage, fitted with an MTM-20 thickness controller. 173 
Transmission electron microscopy (TEM) images were obtained in a JEOL 1400 (Jeol Ltd, 174 
USA) operating at 80 kV. All nanocapsules suspensions were diluted to a final 175 
concentration of 1 mg/mL polymer in ultrapure water and a 5 μL droplet was deposited on a 176 
glow discharged carbon-coated 200 mesh grid. Negative staining was performed using 2% 177 
phosphotungstic acid (w/v). All images were acquired with an Orius camera (Gatan Inc, 178 
USA).  179 
Cryo-Transmission Electron Microscopy (Cryo-TEM) images were performed using 180 
a JEOL 1400 TEM/STEM operating at 120 kV. NC suspensions at 50 mg.mL-1 polymer 181 
were deposited (5 μL) on a glow discharged carbon grid (Lacey 200 mesh), automatically 182 
blotted for 5 s and plunged into liquid ethane at -175°C by a grid plunge freezer (Leica EM 183 
GP). The samples were kept in liquid nitrogen until analysis. Next, they were transferred to 184 
a pre-cooled cryo-TEM holder (Gatan 914) and observed under 10 pA/cm2 of luminosity, 2 185 
s of exposition and -2 μm of defocus. All images were acquired with a US1000XP camera 186 
(Gatan Inc, USA).  187 
2.8 PFH encapsulation efficiency  188 
For PFH quantification, 500 μL of NC suspension freshly prepared was transferred 189 
to NMR tubes loaded with a stem coaxial insert containing TFA in D2O (12 µmol.mL
-1) as 190 
external standard [32, 35].Freeze-dried samples were also analyzed: 1 mL of freshly 191 
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prepared nanocapsule suspension was freeze-dried during 24h employing an Alpha-1-2 LD 192 
apparatus (Christ, France). Afterwards, they were hermetically sealed with a rubber cap 193 
and stored at -20°C until analysis. A total volume of 1 mL of chloroform then was introduced 194 
into the sealed tube by a needle, the suspension was vortexed (5 cycles of 30 seconds) 195 
and centrifuged at 0°C for 10 minutes at 1000 RPM. The organic solution was collected in a 196 
cold room at 4°C and introduced into an NMR tube loaded with the stem coaxial insert 197 
containing TFA in D2O (12 µmol.mL
-1). All spectra were obtained by a Bruker Avance 300 198 
(400 MHz) operating at 4°C. The total amount of encapsulated PFH was determined based 199 
on a PFH calibration curve. For each NC sample, the integration of the TFA peak at  -76.5 200 
ppm was determined as 3 and the resulting integration of the PFH CF3 at -81.2 ppm was 201 
used to calculate the PFH concentration in the NMR tube based to the equation of the 202 
calibration curve. 203 
2.9 Cell viability  204 
The cytotoxicity of all NCs was evaluated in two distinct cell lines obtained from ATCC 205 
(USA). Human endothelial umbilical vein cells (HUVEC) were cultivated in DMEM 206 
supplemented with 50 U.mL-1 of penicillin, 50 U.mL-1 of streptomycin and 10% FBS. Murine 207 
macrophage-monocytes (J774.A1cell line) were cultivated in RPMI 1640 medium 208 
supplemented with 50 U.mL-1 of penicillin, 50 U.mL-1 of streptomycin and 10% heat 209 
inactivated FBS. All cells were cultivated at 37°C at 5% CO2 in a humidified atmosphere; 210 
they were splitted twice a week by trypsinisation for HUVEC and scraping for J774.A1. To 211 
assess the in vitro cytotoxicity, the MTT assay that evaluates the mitochondrial activity was 212 
employed [36]. A total volume of 100 µL of the cells suspension was seeded into 96 well 213 
plates (TPP, Switzerland) at a concentration of 8x103 cells/well or 2x103 cells/well for 24 214 
and 72h of incubation, respectively. The cells were pre-incubated for 24h and 100 µL of a 215 
serial dilution of NCs (1.0x10-2 to 10 mg.mL-1) was added to the medium. After 24 or 72h of 216 
incubation, 20 µL of MTT solution at 5mg/mL(3-(4,5-dimethylthiazol-2-yl)-2,5-217 
diphenyltetrazolium bromide) (Sigma, France) was added to each well. After 1hof 218 
incubation, the medium was then aspired and replaced by 200 µL of mL dimethylsulfoxide 219 
(ACS grade, BioBasic Inc, France). The absorbance     was measured with a microplate 220 
reader (LAB Systems Original Multiscan MS, Finland) at 570 nm and the cell viability was 221 
calculated according to Eq. 2, where [A]control corresponds to the absorbance of untreated 222 
control cells: 223 
       
          
      Eq. 2 224 
  225 
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 226 
2.10 In vitro Ultrasound Characterization 227 
Ultrasound images were acquired in a degassed water bath maintained at 37°C 228 
equipped with acoustic absorbing rubber. All NC were previously degassed and 0.8 mL 229 
were transferred to a silicone tube to a final 50 mg.mL-1 suspension. Suspensions of 230 
Sonovue® 0.1%, PVA 0.7% and nanoparticles (NP) produced with PLA-C8F17 (without PFH) 231 
were used as controls. In vitro ultrasound imaging experiments were performed using an 232 
ultrafast programmable ultrasound scanner (Aixplorer, Supersonic Imagine, Aix-En-233 
Provence, France). The scanner was equipped with a 5 MHz linear array transducer (128 234 
elements, 0.2 mm pitch) able to emit and accumulate a series of plane waves. The US 235 
focus was placed at the center of the silicone tube relative to the transducer at 3 cm depth. 236 
The pulse repetition frequencies used in this experiment was 50 Hz. The images were 237 
obtained using a plane-wave B-mode sequence [37] at 0.1 MPa peak negative pressure. 238 
Conventional focused B-mode (0.1 MPa) and contrast specific mode (~0.2 MPa, executed 239 
by pulse inversion and amplitude modulation) images were initially performed for each 240 
sample independently. Imaging and monitoring pulses were 1 cycle long at 5 MHz. Finally, a 241 
disruption pulse was emitted (~5 MPa peak negative pressure, 100 cycles long, which 242 
corresponds to 20 µs) and the imaging process was repeated, with 65 B-mode images for 243 
the total 140 ms pulse sequence. Plane-wave images were acquired at a frame rate of 100 244 
Hz and all data was transferred to a computer for analysis at Matlab (Mathworks, Natick, 245 
MA, USA). The backscattered intensity of the samples was obtained by averaging the 246 
power of the first and last image of the video in the region-of-interest (the silicone tube). 247 
The resulting intensities were subtracted by the backscattered intensity obtained with the 248 
tube filled with Milli-Q water.   249 
Insert Figure 1 here 250 
2.11 Focused Ultrasound 251 
Focused ultrasound experiments were performed to assess the ability to destroy NCs. 252 
100 µL of 5 mg.mL-1 NC suspension were transferred to a 96 well microplate (OptiCell®) 253 
that was placed in a support positioned at the center of the chamber. A 2.25 MHz 254 
transducer (Imasonics, Voray-sur-l'Ognon, France) was focused (38 mm f/d=1) separately at 255 
each microplate well and single bursts of 5 cycles were transmitted by a waveform 256 
generator and amplified to 12.3 MPa peak-negative pressure by a radio frequency 257 
amplifier[26]. 258 
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 259 
2.12 Statistical analysis 260 
The statistical analysis was performed using Statistica™ 8.0 software (StatSoft Inc., Tulsa, 261 
USA). The data was analyzed by two-sided Student’s t-test and a statistical significance 262 
was set at the level of p<0.05. 263 
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3. Results and discussion 264 
3.1 Synthesis and characterization of fluorinated polymers 265 
Polylactide polymers functionalized with either alkyl or fluorinated end-groups of five 266 
distinct lengths were synthesized by ring opening polymerization of D,L-lactide as described 267 
previously [32]. The end-groups are composed of linear carbon chains substituted by 268 
fluorine or hydrogen atoms; henceforth, the synthesized polymers were designated 269 
according to the terminal group chemistry and length of fluorinated unit as PLA-C6H13, PLA-270 
C3F7, PLA-C6F13, PLA-C8F17, PLA-C11F23 and PLA-C13F27. 271 
All synthesis products were initially characterized by the presence of the lactide 272 
signals at 1.60 and 5.23 ppm and the new ester linkage performed with the fluorinated or 273 
alkylated alcohol initiators by 1H-NMR (Figure 2A). As previously observed by Böhmer et 274 
al., all the fluorinated polymers exhibited a significant shift of the –CH2O– signal compared 275 
with the correspondent initiator from 4.1 ppm to 4.55 and 4.74 ppm (Supplementary 276 
information, Figures S1 and S2), indicating that the chemical environment of those groups 277 
were severely influenced by the PLA backbone as well as by the adjacent CF2 units [38]. 278 
Accordingly, the –CH2O– intensity was splitted into two signals with multiplicity of two 279 
triplets due to the strong coupling with both fluorine atoms and the geminal proton in the 280 
same order of magnitude (~13 Hz), which confirmed the synthesis of fluorinated PLA 281 
polymers. Also, the fluorinated derivatives exhibited a shift of the –CF2CH2– signals while 282 
other CF2 and CF3 (-78.9 to -79.0 ppm) resonances were similar to each specific precursor 283 
as displayed in the 19F spectra (Figure 2B). The formation of the non-fluorinated derivative, 284 
PLA-C6H13, was verified by the –CH2O– signal shift from 3.60 to 4.14 ppm of the initiator. 285 
As shown in Table 1, a relative good agreement between the experimental molar 286 
masses determined by SEC and the molar masses targeted at 20 000 g.mol-1 for all the 287 
derivatives was observed (Supplementary infromation Figure S3). The Mn was also 288 
determined by 1H-NMR analysis on the basis of the integration ratio of peak at 5.23 ppm 289 
(methine proton of lactide) and 4.55 - 4.74 ppm (methylene protons adjacent to the CF 290 
chain) (Figure 2A). Slightly lower Mn were calculated than using SEC, around 18 000 g.mol
-291 
1, which may be attributed to the difference of polymer conformation with poly(methyl 292 
methacrylate) standards.  293 
The end-modified polymers were also characterized by DSC. They all displayed the 294 
same glass-transition temperature (Tg), from 50 to 53ºC, similar to unmodified PLA 295 
polymers of similar molar mass (Table 1)[34, 39]. Hence, the small molecular weight end-296 
group did not impact the Tg of high molar mass polylactide. 297 
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Insert Figure 2 here 298 
Insert Table 1 here 299 
3.2 PFH Nanocapsules 300 
Fully fluorinated liquid perfluorocarbons usually display high vapor pressure values – 301 
29.1 kPa at 25°C for PFH – and restricted solubility in organic solvents due to their 302 
fluorophilic character [40]. As a result, they tend either to phase separate or to evaporate 303 
during the formulation of nano or microcapsules by solvent emulsion-evaporation, reducing 304 
the PFC encapsulation efficacy [27, 28]. Therefore, fluorinated end-groups with distinct 305 
lengths were introduced into the PLA structure to promote “fluorous – fluorous” interactions 306 
between the polymer and liquid perfluorocarbons and enhance PFH encapsulation into 307 
nanocapsules. This strategy was shown efficient recently for a high-boiling point PFC: 308 
perfluorooctyl bromide [32]. The features of NCs formulated with fluorinated polymers, such 309 
as morphology, size, surface charge and PFH encapsulation efficiency were compared with 310 
samples produced with the non-fluorinated polymer PLA-C6H13.  311 
Initial characterization demonstrated that all NC were spherical with smooth surfaces as 312 
shown by TEM and SEM images (Figure 3). The Z-average size was around 150 nm – in 313 
agreement with electron microscopy observations – with a negative ζ–potential around    -8 314 
mV and a low polydispersity below 0.15, regardless of end-group chemistry or fluorinated 315 
length as displayed in Table 2.  316 
Insert Table 2 here 317 
Insert Figure 3 here 318 
Encapsulated PFH was effectively visualized by Cryo-TEM images, revealing spherical 319 
core-shell morphologies constituted by thin polymeric layers surrounding the electron-dense 320 
perfluorocarbon as shown in Figure 4 for PLA-C6H13, PLA-C3F7, PLA-C8F17 and PLA-321 
C13F27. All samples displayed capsules containing distinct amounts of PFH, exhibiting dark 322 
cores with a wide intensity range and also presented apparently unloaded polymeric 323 
nanoparticles, an indication of inhomogeneous encapsulation. From these images, no 324 
morphological distinction among polymer end-group chemistry or F-length was observed. 325 
Some capsules also presented a predominant lighter core or bright spots within the 326 
perfluorocarbon phase (white arrows in Figure 4). Such areas might arise from the freezing 327 
process: as PFH retracts when it solidifies, low PFH densities regions appear in the 328 
capsules with probable coexistence of solid PFH (dark) with gaseous PFH (light). After 329 
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exposure to the electron beam radiation, partial melting of the solid PFH occurs and light 330 
regions becomes darker (Supplementary Information, Figure S4). Those observations are 331 
consistent with Lattin et al. that reported the increased frequency of bright nanoemulsion 332 
droplets for the lower boiling point perfluoropentane (Bp=29°C) in comparison with 333 
perfluorohexane (Bp=56°C) and perfluoroheptane (Bp=82°C) [41] and from our own 334 
observations with PFOB [32, 42].  335 
Insert Figure 4 here 336 
The total encapsulated PFH was then quantified by 19F-NMR for NC suspensions 337 
either freshly prepared or after freeze-drying. The samples prepared with the non-338 
fluorinated polymer (PLA-C6H13) exhibited an encapsulation efficiency of 9.2±0.1% for 339 
freshly prepared suspensions and 4.0±0.5% after freeze drying, in agreement with results 340 
obtained for nanocapsules formulated with regular PLGA polymers [30]. All NC formulated 341 
with F-polymers showed a 2-fold increase in the total PFH encapsulation compared to PLA-342 
C6H13 as exhibited in Figure 5. A maximum encapsulation efficiency of 15±1.0% for 343 
suspensions and a 9.5±0.8% plateau for freeze-dried samples was reached, although 344 
without significant difference as a function of fluorinated chain length. Obviously, the freeze-345 
drying process induced the loss of non-encapsulated PFH droplets, as previously observed 346 
for PFOB NCs [42], although no free PFH could be observed by cryo-TEM. These results 347 
suggest a preferential interaction between fluorinated polymers and PFH, independently of 348 
the fluorinated end-chain length, reducing the PFH loss during solvent evaporation and 349 
increasing the final encapsulation efficiency. Nonetheless, the PFH solubility and volatility 350 
still prevents higher encapsulation. Comparatively, mPEG-polycaprolactone polymers 351 
containing terminal C3F7 groups were also successful in enhancing of PFH entrapment into 352 
NCs around ~15% as reported by Li et al. [31]. 353 
Insert Figure 5 here 354 
3.3 In vitro cytotoxicity of NCs 355 
The use of fluorinated-compounds for biomedical applications is usually limited 356 
because of their persistence and consequent toxicity in the organism [43]. Indeed, the 357 
stable C-F bond hinders an effective enzymatic or metabolic degradation that results in low 358 
excretion profiles, especially for linear fluorinated compounds longer than C7F15 [44, 45]. To 359 
assess the in vitro impact of fluorinated end-groups with distinct lengths on cellular viability, 360 
NCs formulated with fluorinated polymers were incubated with two distinct cell lines, human 361 
umbilical vein endothelial (HUVEC) and murine macrophage-like (J774.A1) during 24h or 362 
72h. The MTT assays showed that NCs did not inhibit HUVEC growth after 24h or 72h, 363 
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independently of NC concentration, end-group chemistry or fluorinated end-group lengths 364 
(Figure 6). For J774.A1, an inhibition down to 75% was observed for 10 mg/mL NCs after 365 
24h of exposure. After 72h exposure, cell viability decreased down to 75 and 50% of 366 
controls at NC concentrations of 4 and 10 mg/mL, respectively (Figure 6). For both cell 367 
lines, no specific toxicity was induced due to the presence of the fluorinated groups. One 368 
should note that the reduction of cell viability of J774.A1 cells was only observed for very 369 
high NC concentrations. In addition, the distinct profiles for the two cell lines arise from the 370 
ability of J774.A1 to internalize faster and to a higher extent NCs than HUVEC [46]. 371 
Although only a limited in vitro cytotoxicity was observed, additional in vivo studies are 372 
required to investigate the effects resulting from the prolonged exposure to NCs.  373 
Insert Figure 6 here 374 
3.4 In vitro Ultrasound imaging 375 
The imaging ability of NCs was evaluated in vitro using a plane-wave B-mode 376 
imaging system based on compounded plane-wave ultrasound transmissions[47].  All 377 
images were obtained with fixed 50 mg.mL-1 concentrations of NC at 37°C and compared to 378 
the background gray-scale level produced by ultrapure water. At this temperature, the PFH 379 
vapor pressure increases to 48.6 kPa – against 29.1 kPa at 25°C – and potentially favors a 380 
gas-phase nucleation. Ultrasound images obtained in the conventional focused B-mode 381 
displayed a significant contrast enhancement (p<0.001) arising from NC formulated with 382 
fluorinated polymers (from 1.5 x104 until 5.5x104 arbitrary units, a.u.) compared to those 383 
produced with PLA-C6H13 (0.5x10
4 a.u.) (Figure 7). Moreover, significant differences were 384 
observed between fluorinated samples (p<0.001). Additionally, the fluorinated NCs 385 
generated contrast specific echoes, enhancing the backscattering intensities from 10-fold to 386 
40-fold higher than PLA-C6H13. Again, significant differences were observed between 387 
fluorinated samples except for PLA-C11F23 and PLA-C13F27 which are not statistically 388 
different. For both ultrasound-imaging modalities, all samples exhibited long-lasting 389 
echogenicity for more than 10 minutes. As expected, Sonovue® greatly increased the 390 
ultrasound contrast compared to all NCs (from 12-fold to 35-fold) in the conventional 391 
focused B-mode and contrast specific mode due to its micrometer size and its gaseous 392 
core. In absence of PFH, the PLA-C8F17 nanoparticles (NP in Figure 7) and PVA solution 393 
did not yield any significant signal enhancement.  394 
Insert Figure 7 here 395 
The acoustic enhancement observed for samples formulated with fluorinated 396 
polymers indicates that the total amount of PFH is a key parameter required to modulate 397 
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the echogenicity of NCs, given these possess similar sizes. Interestingly, polymers 398 
containing longer F-units, such as PLA-C11F23 and PLA-C13F27, exhibited higher 399 
backscattering compared to shorter or non-fluorinated NCs. Given NC sizes are similar, 400 
such variation of echogenicity with F-length might be related to an increase of NC density 401 
that further affects the scattering cross section of the NCs as described in the introduction 402 
[9]. The fluorinated initiator density increases from 1.6 g.cm-3 to 1.73 g.cm-3 for C3F7 to 403 
C13F27 (as provided by the supplier) whereas the density of PLA is close to the one of PLGA 404 
(1.28 g.cm-3)[48]. In addition, as we expect fluorinated moieties to position at the 405 
PFH/polymer interface, they might provide nuclei for PFH cavitation/bubble nucleation [49]. 406 
The presence of these bubbles could also explain the harmonic response of fluorinated 407 
NCs as no contrast specific signal can be observed for non-fluorinated ones (obtained with 408 
PLA-C6H13) or with nanoparticles (NP, Figure 7). 409 
At higher acoustic pressures (peak negative pressure ~5 MPa), a signal 410 
enhancement is observed after 20 ms for all NCs formulated with fluorinated polymers, 411 
most probably indicating that the shell was disrupted from a certain population of capsules 412 
(as illustrated for PLA-C8F17 in Figure 8). For these samples, the PFH is possibly 413 
completely vaporized causing the polymeric shell to shatter and allow the gas-phase to 414 
freely vibrate, which momentarily increases the echo. This transitory higher echogenicity 415 
then decreases back to the initial echogenicity as the gas bubble is dissolved or destroyed 416 
in a similar profile as observed for microbubbles [47]. 417 
Insert Figure 8 here 418 
3.5 PFH vaporization by focused ultrasound  419 
PFH-loaded NCs present an interesting potential to release chemotherapeutics 420 
inside solid tumors after local accumulation driven by the EPR effect, provided they are 421 
PEGylated and can long circulate in the blood stream. Their great advantage resides on the 422 
acoustic-sensitivity of the low boiling point PFH that can be remotely induced to vaporize by 423 
focused ultrasound (FUS) to trigger the release of co-encapsulated drug locally. To 424 
evaluate the ability of PFH to undergo acoustic drop vaporization under FUS, NCs were 425 
exposed to FUS acoustic pulses and analyzed morphologically by cryo-TEM.  426 
All samples displayed a predominant population of spherical and intact NCs with 427 
core-shell morphology (Figure 9 top). However, a distinct population of capsules that 428 
exhibited deformed structures according to polymer end-chemistry were also visualized: 429 
samples produced with PLA-C6H13 exhibited some buckled NCs, suggesting that a partial 430 
PFH vaporization occurred and produced only a localized distortion of the polymeric shell. 431 
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For NCs prepared with fluorinated polymers – PLA-C3F7, PLA-C8F17 and PLA-C13F27 – more 432 
intense shell deformations led to a complete morphological change that culminated, in 433 
many cases, in capsule disruption and observation of debris, some of them at the 434 
micrometric size range (white arrows) (Figure 9 bottom). It is important to emphasize that 435 
the focus of the ultrasonic beam is small  (less than 1 μL or 1mm3) compared to the total 436 
volume of the samples, a factor that contributed to reduce the number of viewable debris 437 
during cryo-TEM.. The presence of PFH inside several capsules indicates that longer FUS 438 
exposition time intervals are still required for homogeneous NC disruption.    439 
 Insert Figure 9 here 440 
Comparatively, corresponding samples were submitted to heating at 60°C for 10 441 
minutes in an oil bath – above the PFH boiling point (56°C). The results showed no 442 
morphological discrepancy or size variation compared to the control group (Supplementary 443 
information, Figures S5 and S6), thus suggesting that the ultrasound mechanical effects 444 
are required in addition to the thermal ones to promote a more effective vaporization as 445 
previously reported [50]. Additionally, as the temperature in focal area of FUS might 446 
become higher than 65°C within 1s [25], the polymer shell might be above its Tg of 52°C 447 
(Table 2) – therefore making polymer shell deformation easier.  448 
 449 
4. Conclusion 450 
We have successfully synthesized polylactide polymers containing fluorinated end-groups 451 
of different lengths, from C3F7 until C13F27 that were formulated into nanocapsules 452 
containing a perfluorohexane core. The employment of fluorinated polymers increased by 453 
2-fold the encapsulation efficiency of perfluorohexane into nanocapsules, although no effect 454 
of fluorine chain length was observed. Fluorination of the polymers did not induce any 455 
specific in vitro cytotoxicity towards HUVEC and J774.A1 cell lines. Nanocapsules 456 
formulated with fluorinated polymers enhanced their acoustic response compared to PLA-457 
C6H13 in both fundamental and harmonic ultrasound imaging modalities. An increased 458 
echogenicity and harmonic response was observed as the fluorinated chain-length 459 
increased, probably due to an increase of density and promotion of bubble nucleation. 460 
When submitted to focused ultrasound, both intact and exploded nanocapsules could be 461 
observed, also with end-group dependency, indicating that the perfluorocarbon was partly 462 
vaporized. These results pave the way to theranostic perfluorohexane nanocapsules co-463 
encapsulating a drug for precision delivery using focused ultrasound.  464 
  465 
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Tables and Figures captions 612 
Table 1. Number-average molar masses (Mn) obtained by SEC/1H-NMR, dispersity and glass-613 
transition temperature (Tg) of all synthesized polymers. 614 
 615 
Table 2. Z-average size, polydispersity index and ζ–potential for nanocapsules formulated with 616 
fluorinated and non-fluorinated polymers. Data are presented as mean±SD (n=3). 617 
 618 
Figure 1: Schematic representation (A) and real view (B) of the US set-up. 619 
  620 
Figure 2. 1H-NMR spectra of all synthesized polymers with enlargement of the corresponding 621 
lactide and ester linkage signals (A). Magnified CF3 and CF2 regions in the 19F spectra for PLA-C3F7, 622 
PLA-C6F13, PLA-C8F17, PLA-C11F23 and PLA-C13F27 (B). The 1H and 19F peak assignments are 623 
indicated in the insert. All samples were dissolved in CDCl3.  624 
  625 
Figure 3. Transmission (left) and scanning electron microscopy images (right) for nanocapsules 626 
formulated with fluorinated and non-fluorinated polymers. 627 
  628 
Figure 4. Cryo-TEM images of nanocapsules formulated with fluorinated PLA-C3F7, PLA-C8F17 and 629 
PLA-C13F27 as well as non-fluorinated PLA-C6H13 polymers. The white arrows show the bright 630 
regions within the nanocapsules. 631 
  632 
Figure 5. PFH encapsulation efficiency for NCs freshly prepared suspension (red bars) or submitted 633 
to freeze-drying (blue bars). 634 
  635 
Figure 6. Cell viability as a function of NC concentration for HUVEC (top) and J774.A1 (bottom) at 636 
24h (left) and 72h (right). All results are presented as mean ± SD (N=2).  637 
  638 
Figure 7. Ultrasound backscattered intensity at the conventional focused B-mode (black 639 
symbols) and contrast specific (red symbols) modalities for PVA, nanoparticles of PLA-640 
C8F17 (NP) and all formulated nanocapsules. The error bars represent the ultrasound signal 641 
variability between the echo-pulses for each sample (about 5% error). Differences between 642 
NC formulated with fluorinated polymers and those produced with PLA-C6H13 were 643 
statistically significant in both modes. Moreover, significant differences were observed 644 
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between fluorinated samples in conventional mode (p<0.001). In contrast specific imaging 645 
Again, significant differences were observed between fluorinated samples except for PLA-646 
C11F23 and PLA-C13F27 which are not statistically different. 647 
 648 
 649 
Figure 8. Sequential ultrasonic images of PLA-C8F17 nanocapsules prior (-200 ms) and after 650 
exposure to FUS (from 20 to 1000 ms). The average amplitude signal is presented for each image 651 
(bottom). The scale bar corresponds to 1 mm.  652 
  653 
Figure 9. Cryo-TEM images of nanocapsules after focused ultrasound exposure. Intact/spherical 654 
(top) and buckled or debris of nanocapsules (bottom) were observed for all samples. All scale bars 655 
represent 100 nm.  656 
 657 
